Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Saved in:
| Title: | Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. |
|---|---|
| Authors: | Tutrone R; Chesapeake Urology, Towson, MD, USA. Electronic address: rtutrone@uniteduro.com., Saad F; University of Montreal Hospital Centre, Montreal, QC, Canada., George DJ; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA., Tombal B; Institut de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium., Bailen JL; First Urology, Jeffersonville, IN, USA., Cookson MS; Department of Urology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA., Saltzstein DR; Urology San Antonio, San Antonio, TX, USA., Hanson S; Pfizer, Inc., New York, NY, USA., Brown B; Myovant Sciences, Inc., Brisbane, CA, USA., Lu S; Myovant Sciences, Inc., Brisbane, CA, USA., Fallick M; Myovant Sciences, Inc., Brisbane, CA, USA., Shore ND; Carolina Urologic Research Center and GenesisCare USA, Myrtle Beach, SC, USA. |
| Source: | European urology oncology [Eur Urol Oncol] 2024 Aug; Vol. 7 (4), pp. 906-913. Date of Electronic Publication: 2023 Dec 23. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38143206 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Tutrone+R%22">Tutrone R</searchLink>; Chesapeake Urology, Towson, MD, USA. Electronic address: rtutrone@uniteduro.com.<br /><searchLink fieldCode="AU" term="%22Saad+F%22">Saad F</searchLink>; University of Montreal Hospital Centre, Montreal, QC, Canada.<br /><searchLink fieldCode="AU" term="%22George+DJ%22">George DJ</searchLink>; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Tombal+B%22">Tombal B</searchLink>; Institut de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Bailen+JL%22">Bailen JL</searchLink>; First Urology, Jeffersonville, IN, USA.<br /><searchLink fieldCode="AU" term="%22Cookson+MS%22">Cookson MS</searchLink>; Department of Urology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.<br /><searchLink fieldCode="AU" term="%22Saltzstein+DR%22">Saltzstein DR</searchLink>; Urology San Antonio, San Antonio, TX, USA.<br /><searchLink fieldCode="AU" term="%22Hanson+S%22">Hanson S</searchLink>; Pfizer, Inc., New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Brown+B%22">Brown B</searchLink>; Myovant Sciences, Inc., Brisbane, CA, USA.<br /><searchLink fieldCode="AU" term="%22Lu+S%22">Lu S</searchLink>; Myovant Sciences, Inc., Brisbane, CA, USA.<br /><searchLink fieldCode="AU" term="%22Fallick+M%22">Fallick M</searchLink>; Myovant Sciences, Inc., Brisbane, CA, USA.<br /><searchLink fieldCode="AU" term="%22Shore+ND%22">Shore ND</searchLink>; Carolina Urologic Research Center and GenesisCare USA, Myrtle Beach, SC, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101724904%22">European urology oncology</searchLink> [Eur Urol Oncol] 2024 Aug; Vol. 7 (4), pp. 906-913. <i>Date of Electronic Publication: </i>2023 Dec 23. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+B%2EV%22">Elsevier B.V </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>101724904 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2588-9311 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225889311%22">25889311 </searchLink><i>NLM ISO Abbreviation: </i>Eur Urol Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38143206 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.euo.2023.11.024 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 906 Titles: – TitleFull: Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Tutrone R – PersonEntity: Name: NameFull: Saad F – PersonEntity: Name: NameFull: George DJ – PersonEntity: Name: NameFull: Tombal B – PersonEntity: Name: NameFull: Bailen JL – PersonEntity: Name: NameFull: Cookson MS – PersonEntity: Name: NameFull: Saltzstein DR – PersonEntity: Name: NameFull: Hanson S – PersonEntity: Name: NameFull: Brown B – PersonEntity: Name: NameFull: Lu S – PersonEntity: Name: NameFull: Fallick M – PersonEntity: Name: NameFull: Shore ND IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 08 Text: 2024 Aug Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 2588-9311 Numbering: – Type: volume Value: 7 – Type: issue Value: 4 Titles: – TitleFull: European urology oncology Type: main |
| ResultId | 1 |
